Long-lived COVID or post-COVID-19 syndrome is an emerging and complex health problem that is already affecting humanity and may have an impact in future post-Coronavirus pandemics. the most common symptoms Fatigue, shortness of breath, and cognitive dysfunction, but also others affecting the musculoskeletal, cardiac, and central nervous systems And this, in general, affects the daily functioning of those affected.
A study conducted in Israel provided further evidence. Benefits of vaccination against COVID-19 as a way to reduce the risk and impact of COVID in the long run.
It was already known that long-term symptoms of covid may fluctuate or recur over time. The most common are fatigue (about 58%), shortness of breath (24%), joint pain (19%), chest pain (16%), headache 2.3 (44%), palpitations (11%), Physical limitations depression (12%) and insomnia (11%). these symptoms They may arise after initial recovery from an acute episode of COVID-19 or may be persistent symptoms that do not resolve after infection.
The new study was carried out by researchers from the Azraeli School of Medicine at Bar-Ilan University in Israel. They showed that vaccination with at least two doses of vaccines developed by the companies Pfizer and BioNTech dramatically reduced most of the long-term symptoms that individuals report months after contracting the coronavirus infection.
on research, Eight of the ten most common symptoms were reported 50-80% less frequently in individuals who received at least two doses of the COVID-19 vaccine compared to those who received no doses.
The study was published in the journal NPJ Vaccineseditorial group that publishes Nature. It was led by Professor Michael Edelstein of Bar-Ilan University in collaboration with the infectious disease and informatics teams of three of the Faculty’s affiliated hospitals in northern Israel: Baruch Padeh Medical Center, Ziv Medical Center and Galilee Medical Center. Paul Otiku, a doctoral student at Azarili College in Bar-Ilan, did most of the statistical analysis.
About 3,500 adults from Israel participated in the study, Which was conducted between July and November 2021. Those individuals completed a survey available in four commonly spoken local languages—Hebrew, Arabic, Russian and English—with a range of questions about prior COVID-19 infection, vaccination status, and any symptoms they had. . were experiencing.
More than half of the participants (2,447) declared they had no previous infection with the coronavirus, while 951 were infected. Of those who did get the infection, 637 (67%) received at least two doses of the vaccine. Of the 2,447 individuals who did not report any previous infection, 21 (0.9%) received a single dose, 1,195 (48.8%) received two doses, 744 (30.4%) received three doses, and the rest Not vaccinated (19.9%).
The researchers compared vaccinated individuals with non-vaccinated individuals for self-reported post-acute symptoms. After adjusting for factors such as age and time from transition to survey response, found that vaccination with two or more doses of messenger RNA vaccine was associated with a lower risk of reporting Most common long lasting COVID symptoms.
In the current study population, the most common self-reported symptoms—fatigue, headache, weakness of the limbs, and persistent muscle pain—were reduced by 62%, 50%, 62%, and 66%, respectively. Shortness of breath and persistent muscle pain reduced by 70%.
The study, which received funding from the Harvey Goodstein Foundation, contributed to the world’s lack of information on the impact of vaccination on COVID for a long time. “We do not fully understand what happens in the months and years after COVID-19 in terms of physical and mental health and well-being,” Professor Edelstein said.
“Since Long COVID affects so many people, it was important for us to see if vaccines can help relieve symptoms. It is becoming increasingly clear that vaccines not only protect against disease, but, as the results of this study show, against the long-term effects of COVID-19, Which sometimes change lives”, highlighted the expert.
Their study was the first of an ongoing project launched to follow a large group of individuals from all regions of Israel to assess the effects of vaccines on long-term quality of life, various forms of the coronavirus, and long-term COVID symptoms. be understood. ,
The results of another study in Italy were also recently released. It has been suggested that three doses of COVID-19 vaccines are associated with a lower risk of developing COVID in the long term among non-hospitalized patients.
The Italian team set out to investigate the effect of a triple dose of vaccination on the development of the long-term covirus. For this, they turned to health professionals who had received three doses of the messenger RNA vaccine and who did not require hospitalization if they developed a prolonged infection. A total of 739 individuals with a mean age of 42.8 years (25.4% male) were included, of whom 31% developed chronic COVID and 16% of these individuals had received three doses of the vaccine.
The number of doses of the vaccine was also associated with prolonged COVID development, ranging from 41.8% among unvaccinated individuals, 30% in those with a single dose, 17.4% after two doses, and 16% among those who had The pass was a third dose. Vaccination. The work was published in the journal jama,